Neurocircuitry of Addiction

被引:0
|
作者
George F Koob
Nora D Volkow
机构
[1] Committee on the Neurobiology of Addictive Disorders,
[2] The Scripps Research Institute,undefined
[3] National Institute on Drug Abuse,undefined
来源
Neuropsychopharmacology | 2010年 / 35卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Drug addiction is a chronically relapsing disorder that has been characterized by (1) compulsion to seek and take the drug, (2) loss of control in limiting intake, and (3) emergence of a negative emotional state (eg, dysphoria, anxiety, irritability) reflecting a motivational withdrawal syndrome when access to the drug is prevented. Drug addiction has been conceptualized as a disorder that involves elements of both impulsivity and compulsivity that yield a composite addiction cycle composed of three stages: ‘binge/intoxication’, ‘withdrawal/negative affect’, and ‘preoccupation/anticipation’ (craving). Animal and human imaging studies have revealed discrete circuits that mediate the three stages of the addiction cycle with key elements of the ventral tegmental area and ventral striatum as a focal point for the binge/intoxication stage, a key role for the extended amygdala in the withdrawal/negative affect stage, and a key role in the preoccupation/anticipation stage for a widely distributed network involving the orbitofrontal cortex–dorsal striatum, prefrontal cortex, basolateral amygdala, hippocampus, and insula involved in craving and the cingulate gyrus, dorsolateral prefrontal, and inferior frontal cortices in disrupted inhibitory control. The transition to addiction involves neuroplasticity in all of these structures that may begin with changes in the mesolimbic dopamine system and a cascade of neuroadaptations from the ventral striatum to dorsal striatum and orbitofrontal cortex and eventually dysregulation of the prefrontal cortex, cingulate gyrus, and extended amygdala. The delineation of the neurocircuitry of the evolving stages of the addiction syndrome forms a heuristic basis for the search for the molecular, genetic, and neuropharmacological neuroadaptations that are key to vulnerability for developing and maintaining addiction.
引用
收藏
页码:217 / 238
页数:21
相关论文
共 50 条
  • [41] Shared Behavioral and Neurocircuitry Disruptions in Drug Addiction, Obesity, and Binge Eating Disorder: Focus on Group I mGluRs in the Mesolimbic Dopamine Pathway
    Yohn, Samantha E.
    Galbraith, Jordan
    Calipari, Erin S.
    Conn, P. Jeffrey
    ACS CHEMICAL NEUROSCIENCE, 2019, 10 (05): : 2125 - 2143
  • [42] Disordered neurocircuitry in mood disorders
    Mann, JJ
    BIOLOGICAL PSYCHIATRY, 2004, 55 : 1S - 1S
  • [43] Neurocircuitry for modeling drug effects
    Noori, Hamid R.
    Spanagel, Rainer
    Hansson, Anita C.
    ADDICTION BIOLOGY, 2012, 17 (05) : 827 - 864
  • [44] Defining the neurocircuitry of exercise hyperpnoea
    Paterson, David J.
    JOURNAL OF PHYSIOLOGY-LONDON, 2014, 592 (03): : 433 - 444
  • [45] Neuroimaging and neurocircuitry models in OCD
    Braus, DF
    PHARMACOPSYCHIATRY, 2005, 38 (05) : 232 - 232
  • [46] Neurocircuitry of limbic dysfunction in anorexia nervosa
    Lipsman, Nir
    Woodside, D. Blake
    Lozano, Andres M.
    CORTEX, 2015, 62 : 109 - 118
  • [47] NEUROCIRCUITRY OF ILLNESS-INDUCED HYPERALGESIA
    WATKINS, LR
    WIERTELAK, EP
    GOEHLER, LE
    MOONEYHEIBERGER, K
    MARTINEZ, J
    FURNESS, L
    SMITH, KP
    MAIER, SF
    BRAIN RESEARCH, 1994, 639 (02) : 283 - 299
  • [48] Inflammation in the Neurocircuitry of Obsessive Compulsive Disorder
    Attwells, Sophia
    Setiawan, Elaine
    Wilson, Alan A.
    Rusjan, Pablo M.
    Mizrahi, Romina
    Miler, Laura
    Sharma, Sarita
    Richter, Margaret Anne
    Houle, Sylvain
    Meyer, Jeffrey
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S332 - S333
  • [49] Neurocircuitry in alcoholism: a substrate of disruption and repair
    Edith V. Sullivan
    Adolf Pfefferbaum
    Psychopharmacology, 2005, 180 : 583 - 594
  • [50] Glutamate neurocircuitry: theoretical underpinnings in schizophrenia
    Schwartz, Thomas L.
    Sachdeva, Shilpa
    Stahl, Stephen M.
    FRONTIERS IN PHARMACOLOGY, 2012, 3